Arrakis raises $75 million series B for RNA-targeting small molecules

Arrakis Therapeutics has raised $75 million in series B financing to advance its pipeline of small-molecule drugs that target RNA. The start-up has spent the past 2 years building a platform to screen compound libraries against RNA molecules that encode proteins considered undruggable. One of those proteins is a cancer-connected transcription factor called Myc. Arrakis has found molecules that may be able to prevent transcription of Myc messenger RNA, thereby lowering levels of the protein.